FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Diltiazem Hydrochloride
Status: Currently in Shortage
»Date first posted: 02/21/2018
»Therapeutic Categories: Cardiovascular

Expand all

Akorn Pharmaceuticals (Revised 02/07/2020)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10) Backorder. Estimated recovery March 2020. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25) Backorder. Estimated recovery March 2020. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26) Backorder. Estimated recovery March 2020 Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05) Backorder. Estimated recovery March 2020. Demand increase for the drug

Athenex Pharmaceutical Division, LLC (Athenex) (New 02/12/2020)

Company Contact Information:
855-273-0154

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 mg/5mL vial (NDC 70860-301-05) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154
50 mg/10mL vial (NDC 70860-301-10) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154
125 mg/25mL vial (NDC 70860-301-25) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 02/07/2020)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
5 mg/mL, 5 mL vial (NDC 0641-6013-10) Inventory is currently available. Additional lots will be scheduled for manufacturing Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 10 mL vial (NDC 0641-6014-10) Product is currently on allocation. Additional lots will be scheduled for manufacturing in the February - March 2020 timeframe. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 30 mL vial (NDC 0641-6015-10) Product is currently on allocation. Additional lots will be scheduled for manufacturing in the February - March 2020 timeframe. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc. (Revised 02/12/2020)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03) Available Other
25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01) Next Delivery and Estimated Recovery: August 2020 Shortage per Manufacturer: Manufacturing Delay Other
50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02) Available Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English